Lower urinary tract symptoms, obesity and the metabolic syndrome

Current Opinion in Urology

Volumn 20, Issue 1, 2010, Pages 7-12

  Moul, Samdeep ^a   McVary, Kevin T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Benign prostatic hyperplasia; C reactive protein; Lower urinary tract symptoms; Metabolic syndrome; Obesity

Indexed keywords

C REACTIVE PROTEIN;

DISEASE ASSOCIATION; DISEASE SEVERITY; EPIDEMIC; HUMAN; HYPERACTIVITY; HYPERINSULINEMIA; INFLAMMATION; INSULIN RESISTANCE; LOWER URINARY TRACT SYMPTOM; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; RISK FACTOR; SCORING SYSTEM;

HUMANS; MALE; METABOLIC SYNDROME X; OBESITY; PROSTATIC HYPERPLASIA; PROSTATISM;

EID: 74549115163     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3283336f3f     Document Type: Review

References (45)

1. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49:651-658.
2. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 2005; 40:121-128.
3. McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care 2006; 12 (5 Suppl):S122-S128.
4. Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 1990; 17:241-246.
5. Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol 2005; 173:1309-1313.
6. Behavioral risk factor surveillance system (database on the Internet). www.cdc.gov/brfss. 2009.
7. McVary KT, Razzaq A, Lee C, et al. Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 1994; 51:99-107.
8. Golomb E, Rosenzweig N, Eilam R, Abramovici A. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl 2000; 21:58-64.
9. Rahman NU, Phonsombat S, Bochinski D, et al. An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat. BJU Int 2007; 100:658-663.
10. Persson K, Pandita RK, Spitsbergen JM, et al. Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 1998; 275 (4 Pt 2):R1366-R1373.
11. Steers WD, Clemow DB, Persson K, et al. The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males. Exp Physiol 1999; 84:137-147.
12. Azadzoi KM, Yalla SV, Siroky MB. Oxidative stress and neurodegeneration in the ischemic overactive bladder. J Urol 2007; 178:710-715.
13. Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001; 54:935-944.
14. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999; 8:29-36.
15. McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005; 174 (4 Pt 1):1327-1433.
16. Rohrmann S, Smit E, Giovannucci E, Platz E. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes 2005; 29:310-316. (Pubitemid 40333230)
17. Joseph MA, Harlow SD, Wei JT, et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 2003; 157:906-914.
18. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
19. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998; 1:157-162.
20. Glynn RJ, Campion EW, Bouchard GR, Silbert JE. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 1985; 121:78-90.
21. Rohrmann S, Smit E, Giovannucci E, Platz EA. Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2004; 159:390-397. (Pubitemid 38200773)
22. Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91:2562-2568.
23. Seim A, Hoyo C, Ostbye T, Vatten L. The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int 2005; 96:88-92.
24. Laven BA, Orsini N, Andersson SO, et al. Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men. J Urol 2008; 179:1891-1895; discussion 5-6.
25. Kristal AR, Arnold KB, Schenk JM, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol 2007; 177:1395-1400; quiz 591.
26. Dahle SE, Chokkalingam AP, Gao YT, et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002; 168:599-604.
27. Kupelian V, McVary KT, Kaplan SA, et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol 2009; 182:616-624; discussion 24-25
28. Cellek S, Rodrigo J, Lobos E, et al. Selective nitrergic neurodegeneration in diabetes mellitus: a nitric oxide-dependent phenomenon. Br J Pharmacol 1999; 128:1804-1812.
29. Sarma AV, Jaffe CA, Schottenfeld D, et al. Insulin-like growth factor-1, insulinlike growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among Black men. Urology 2002; 59:362-367.
30. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39:151-158.
31. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in nondiabetic benign prostatic hyperplasia. Clin Chim Acta 2006; 370 (1-2):89-93.
32. Chokkalingam AP, Gao YT, Deng J, et al. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate 2002; 52:98-105.
33. Rohrmann S, Giovannucci E, Smit E, Platz EA. Association of IGF-1 and IGFBP-3 with lower urinary tract symptoms in the third national health and nutrition examination survey. Prostate 2007; 67:1693-1698. (Pubitemid 350036955)
34. Neuhouser ML, Schenk J, Song YJ, et al. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate 2008; 68:1477-1486.
35. Kupelian V, McVary KT, Barry MJ, et al. Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston Area Community Health survey. Urology 2009; 73:950-957.
36. Platz EA, Kawachi I, Rimm EB, et al. Physical activity and benign prostatic hyperplasia. Arch Intern Med 1998; 158:2349-2356.
37. Gann PH, Hennekens CH, Longcope C, et al. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995; 26:40-49.
38. Dal Maso L, Zucchetto A, Tavani A, et al. Lifetime occupational and recreational physical activity and risk of benign prostatic hyperplasia. Int J Cancer 2006; 118:2632-2635.
39. Lacey JV Jr, Deng J, Dosemeci M, et al. Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China. Int J Epidemiol 2001; 30:341-349.
40. Hong J, Kwon S, Yoon H, et al. Risk factors for benign prostatic hyperplasia in South Korean men. Urol Int 2006; 76:11-19.
41. Rohrmann S, Crespo CJ, Weber JR, et al. Association of cigarette smoking, alcohol consumption and physical activity with lower urinary tract symptoms in older American men: findings from the third National Health And Nutrition Examination Survey. BJU Int 2005; 96:77-82. (Pubitemid 40942873)
42. Orsini N, RashidKhani B, Andersson SO, et al. Long-term physical activity and lower urinary tract symptoms in men. J Urol 2006; 176 (6 Pt 1):2546-2550; discussion 50.
43. Williams PT. Effects of running distance and performance on incident benign prostatic hyperplasia. Med Sci Sports Exerc 2008; 40:1733-1739.
44. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol 2008; 53:1228-1235.
45. Natarajan V, Master V, Ogan K. Effects of obesity and weight loss in patients with nononcological urological disease. J Urol 2009; 181:2424-2429.